Traditional drugs usually inhibit specific protein sites, but many disease-causing proteins lack accessible or unique motifs, leaving them “undruggable.” Targeted Small-molecule drugs have long been the quiet workhorses of modern medicine, slipping inside cells to target disease-driving proteins, even as biologics, immunotherapies, and genetic medicines have taken center stage in recent years. Yet thousands of disease-related proteins remain “undruggable” because they lack the structural pockets needed for traditional inhibitors to bind. In this episode, Markus Warmuth, MD, CEO of Monte Rosa Therapeutics, explains how molecular glue degraders harness the cell’s protein-disposal machinery to eliminate harmful proteins entirely, and how the company’s QUEEN discovery platform is advancing new therapies in cancer and autoimmune disease.

Produced and hosted by Jonathan D. Grinstein, PhD

Audio mixed and mastered by Erick Ziegler

Brought to you by Inside Precision Medicine (SAGE Publishing)

Hosted on Acast. See acast.com/privacy for more information.